Video Resources

Medical experts discuss antimicrobial resistance, carbapenem-sparing strategies and how they handle the issue of antimicrobial resistance in the hospital setting.

The significance of the novel combination of ceftazidime-avibactam.

Professor Jean Chastre
Professor of Medicine, Paris 6 University - School of Medicine.
PP-ZVA-IRL-0040
Date of Preparation: March 2018

ZAVICEFTA API & SmPC


Zavicefta (ceftazidime-avibactam) in clinical practice.

Professor Jean Chastre
Professor of Medicine, Paris 6 University - School of Medicine.
PP-ZVA-IRL-0049
Date of Preparation: March 2018

ZAVICEFTA API & SmPC


Advantages of Zavicefta (ceftazidime-avibactam) vs other treatment options for patient at high risk of harbouring resistant Gram-negative bacteria.

Professor Jean Chastre
Professor of Medicine, Paris 6 University - School of Medicine.
PP-ZVA-IRL-0034
Date of Preparation: March 2018

ZAVICEFTA API & SmPC


Critical need for new alternative treatment options to carbapenems .

Professor Jean Chastre
Professor of Medicine, Paris 6 University - School of Medicine.
PP-ZVA-IRL-0035
Date of Preparation: March 2018

ZAVICEFTA API & SmPC


Current limitation with carbapenem use and their impact on clinical practice.

Professor Jean Chastre
Professor of Medicine, Paris 6 University - School of Medicine.
PP-ZVA-IRL-0036
Date of Preparation: March 2018

ZAVICEFTA API & SmPC


Insights to peers on the significance of Zavicefta (ceftazidime-avibactam) when treating MDR Gram-negative infections .

Professor Jean Chastre
Professor of Medicine, Paris 6 University - School of Medicine.
PP-ZVA-IRL-0039
Date of Preparation: March 2018

ZAVICEFTA API & SmPC


The issue of carbapenem resistance

Dr. Hayley Wickens PhD, FFRPS
Consultant Pharmacist, Anti-Infectives
University Hospital Southampton NHSFT

 

How do you handle the issue of antimicrobial resistance in your hospital?

Matteo Bassetti
Santa Maria Misericordia University Hospital,
Udine, Italy

Xavier Guirao
Hospital Universitari Parc Taulí,
Barcelona, Spain